Primary end-point data for DME drug leaves uncertain path to market for iCo Therapeutics

iCo Therapeutics Inc (TSX-V: ICO), headquartered in Vancouver, Canada has announced top-line results for their eight month visual acuity (VA) primary endpoint in the phase 2 “iDEAL Study”, conducted in collaboration with the JDRF (Juvenile Diabetes Research Foundation). The study was designed to evaluate the efficacy and safety after repeated injections of iCo-007 nucleic acid antisense treatment in patients with diabetic macular edema (DME). The mean change in VA at eight months was approximately minus 11 letters (350 ug monotherapy), minus 21 letters (700 ug monotherapy), minus 14 letters (350 ug + laser arm) and minus 14 letters (350 ug + Lucentis) however, according to the company, some patients in each cohort did show improvements in mean change in VA.